Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Transthyretin Amyloidosis: early-phase trial registry
4 of 9 indexed Transthyretin Amyloidosis trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Transthyretin Amyloidosis: 9 US clinical trials tracked, 4 recruiting.
Transthyretin Amyloidosis is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 3 in Phase 1-2 (earlier-stage). The most active sponsor is The Cleveland Clinic, running 2 of these trials.
Enrollment posture brief
Registry condition transthyretin-amyloidosis
OPEN 4 | RECR 44% | LATE 1 | EARLY 3 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Transthyretin Amyloidosis lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Transthyretin Amyloidosis on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Transthyretin Amyloidosis is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Transthyretin Amyloidosis research.
The Cleveland Clinic accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Typical Transthyretin Amyloidosis enrolment sits around 200 participants.
Median target enrolment is 200 among the 9 trials that report a genuine target (sentinel values excluded). 3 of those (33.3%) plan for fewer than 100 participants.
-
Transthyretin Amyloidosis splits between interventional and observational designs.
5 interventional and 4 observational studies make up this index (55.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis
AstraZeneca
NCT06465810
Acoramidis Transthyretin Amyloidosis Prevention Trial in the Young (ACT-EARLY) Study in Asymptomatic Carriers of a Pathogenic TTR Variant
Eidos Therapeutics, a BridgeBio company
NCT06563895
Prevalence and Prediction of ATTR in Ambulatory Patients With HFpEF
Massachusetts General Hospital
NCT05577819
Characterizing Iodine-124 Evuzumitide (AT-01) in Systemic Amyloidosis
Oregon Health and Science University
NCT05758493
Spectrum of Peripheral and Autonomic Neuropathies in Patients With aTTRwt Amyloidosis and Response to Patisiran Therapy
Austin Neuromuscular Center
NCT05023889
Transthyretin Amyloidosis Outcome Survey (THAOS)
Pfizer
NCT00628745
Screening for Systemic Amyloidosis Via the Ligamentum Flavum
The Cleveland Clinic
NCT03923920
Monitoring of Early Disease Progression in Hereditary Transthyretin Amyloidosis
The Cleveland Clinic
NCT03431896
Prevalence of Transthyretin Cardiac Amyloidosis in Clinically Significant Aortic Stenosis
Mayo Clinic
NCT04899180
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Transthyretin Amyloidosis records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Transthyretin Amyloidosis trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Transthyretin Amyloidosis page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Transthyretin Amyloidosis trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- The Cleveland Clinic sponsors the most Transthyretin Amyloidosis trials on record, review their full trial history before evaluating a specific study. See The Cleveland Clinic's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Transthyretin Amyloidosis condition card totals 9 registered trials; most-linked intervention None. Observational Study.; top US site state Minnesota. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.